Management of hot flashes in women with breast cancer

Current Oncology

Volumn 17, Issue 1, 2010, Pages 81-86

  Kligman, L ^a   Younus, J ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Aromatase inhibitors; Breast cancer; Hot flashes; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CITALOPRAM; CLONIDINE; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GABAPENTIN; LETROZOLE; MEGESTROL; OXYBUTYNIN; PROGESTERONE RECEPTOR; SEROTONIN; TAMOXIFEN; VENLAFAXINE;

ALGORITHM; ARTHRALGIA; BREAST CANCER; BREAST METASTASIS; CLINICAL TRIAL; DRUG EFFICACY; DYSPAREUNIA; EVIDENCE BASED MEDICINE; HAIR DISEASE; HORMONAL THERAPY; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; LIBIDO DISORDER; LIFESTYLE MODIFICATION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRESSORECEPTOR REFLEX; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; RISK FACTOR; SIDE EFFECT; THERMOREGULATION; VAGINAL DRYNESS; WEIGHT GAIN;

EID: 75849143533     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i1.473     Document Type: Review

References (36)

1. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
2. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
3. Coombes RC, Hall E, Gibson LJ, et al. on behalf of the Inter-group Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
4. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6.
5. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-80.
6. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, New-comb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;23:501-9.
7. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000;36:155-64.
8. Hoda D, Perez DG, Loprinzi CL. Hot flashes in breast cancer survivors. Breast J 2003;9:431-8.
9. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999;181:66-70.
10. Sheard MH, Aghajanian GK. Neural release of brain serotonin and body temperature. Nature 1967;216:495-6.
11. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999;13:100-9.
12. Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360:1851-61.
13. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptors. Circulation 1994;89:1943-50.
14. Tanaka M, Sato M, Umehara S, Nishikawa T. Influence of menstrual cycle on baroreflex control of heart rate: comparison with male volunteers. Am J Physiol Regul Integr Comp Physiol 2003;285:R1091-7.
15. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57.
16. Howell A, Cuzick J, Baum M, et al. on behalf of the ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
17. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910-17.
18. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264-72.
19. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol 1992;167:436-9.
20. Freedman R, Woodward S, Brown B, Jawaid J, Pandey G. Biochemical and thermoregulatory effects of behavioral treatment for menopausal hot flashes. Menopause 1995;2:211-18.
21. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63.
22. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
23. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818-24.
24. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008;26:5022-6.
25. Fenlon DR, Corner JL, Haviland JS. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manage 2008;35:397-405.
26. Sexton T, Younus J, Perera F, Kligman L, Lock M. Oxybutynin for refractory hot flashes in cancer patients. Menopause 2007;14:505-9.
27. Younus J, Welch S, Granville H. A case report of using hypnosis to treat hot flashes and rheumatic symptoms. Case Rep Clin Pract Rev 2005;6:103-6.
28. Holmberg L, Anderson H on behalf of the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-5.
29. von Schoultz E, Rutqvist LE on behalf of the Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005;97:533-5.
30. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-13.
31. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-8.
32. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-93.
33. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583-6.
34. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-6.
35. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165:1251-5.
36. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-52.